The Securities and Exchange Commission reportedly cleared an investigation into Cassava Sciences (SAVA), leading SAVA stock to hit a seven-month high Thursday.
On today's stock market, SAVA stock rocketed 35.7% to 51.06.
Last November, the SEC launched an investigation into Cassava's simufilam research. Scientists — who also held short positions in SAVA stock — claimed Cassava manipulated images used in testing of the experimental Alzheimer's treatment.